Injectable biphasic calcium phosphate cements as a potential bone substitute

Bone graft materials must balance osteoconductivity with controlled degradation. While apatitic calcium phosphate cements (CPCs) offer strong bone integration, their limited degradation hinders effectiveness in large defects. Earlier studies established apatitic CPCs as osteoconductive but insufficiently resorbable. This gap motivated investigation into modifying CPC composition to improve degradation without sacrificing structural properties. Prior research has shown that tricalcium phosphate (TCP) exists in α- and β-polymorphic forms with differing solubility. However, no prior work had resolved how combining these phases affects cement behavior. Researchers needed to determine if biphasic TCP could enhance degradation while maintaining injectability and mechanical stability. This uncertainty drove the current study to explore biphasic formulations as a potential solution.

This study aimed to develop and evaluate biphasic calcium phosphate cements (BCPCs) using α/β-tricalcium phosphate (TCP) as a precursor. The goal was to improve the degradation properties of traditional apatitic CPCs while maintaining injectability and mechanical performance. Researchers focused on how varying α/β-TCP ratios influence cement characteristics. They hypothesized that biphasic compositions could enhance resorption rates without compromising structural integrity. The specific problem addressed was the insufficient degradation of monophasic apatitic CPCs in large bone defects. The motivation stemmed from clinical needs for graft materials that degrade in sync with new bone formation. By manipulating precursor phase ratios, the team sought to optimize both osteoconductivity and resorption dynamics.

The study involved heat treatment of commercial α-TCP powder to generate biphasic α/β-TCP powders with varying ratios. These powders were used as precursors for cement formulation. Researchers measured setting time, injectability, and mechanical properties of the resulting BCPCs. In vitro degradation was assessed using dissolution tests and calcium release analysis. Morphological differences between monophasic and biphasic cements were observed using crystal structure analysis. The team compared BCPCs with standard monophasic α-TCP-based CPCs. They evaluated how β-TCP content affected apatite formation during cement hardening. The approach combined material synthesis with mechanical and degradation testing to assess functional performance.

Heat treatment of α-TCP produced biphasic powders with controllable α/β-TCP ratios. BCPCs showed increased setting and injectability times compared to monophasic cements. As β-TCP content increased, apatite formation during hardening decreased. Morphologically, monophasic cements formed plate-like crystals, while BCPCs exhibited needle-like structures. In vitro dissolution rates rose significantly with higher β-TCP content. Calcium release from BCPCs increased proportionally with β-TCP levels. These findings suggest that biphasic compositions enhance degradation without compromising injectability. The results indicate that α/β-TCP mixtures can render apatitic CPCs more resorbable while maintaining structural properties.

The authors propose that biphasic α/β-TCP cements can improve degradation rates of apatitic CPCs. Their findings suggest that β-TCP content directly influences dissolution and calcium release. The needle-like crystal morphology of BCPCs may affect mechanical behavior differently than plate-like structures. The study shows that varying precursor phase ratios allows tuning of cement properties. The observed increase in injectability time with biphasic compositions suggests a trade-off between workability and degradation. These results imply that BCPCs could better match bone regeneration timelines than monophasic cements. The authors propose that this approach offers a practical way to enhance CPC performance for clinical applications. Their findings suggest that biphasic formulations may address current limitations in large bone defect repair.